Leigh Syndrome Associated with TRMU Gene Mutations by Sala Coromina, Julia et al.
Molecular Genetics and Metabolism Reports 26 (2021) 100690
Available online 15 December 2020
2214-4269/© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Short Communication 
Leigh syndrome associated with TRMU gene mutations 
Júlia Sala-Coromina a, Lucía Dougherty-de Miguel a, Javier de las Heras b, 
Amaia Lasa-Aranzasti c, Elena Garcia-Arumi c,d,e, Lidia Carreño d,e, Jose Antonio Arranz f, 
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A B S T R A C T   
tRNA 5-methylaminomethyl-2-thiouridylate methyltransferase (TRMU) deficiency causes an early onset poten-
tially reversible acute liver failure, so far reported in less than 30 patients. We describe two new unrelated 
patients with an acute liver failure and a neuroimaging compatible with Leigh syndrome (LS) due to TRMU 
deficiency, a combination not previously reported. Our report enlarges the phenotypical spectrum of TRMU 
disease.   
1. Introduction 
TRMU is a nuclear gene that encodes the mitochondrial-specific 
tRNA-modifying enzyme: 5-methylaminomethyl-2-thiouridylate meth-
yltransferase. TRMU pathogenic variants were first reported as a mod-
ifier in patients with sensorineural deafness carrying homoplasmic 
m.1555G > A variant in the mitochondrial gene MTRNR1 (OMIM 
*561000) [1]. In 2009, pathogenic variants in TRMU gene were 
described as responsible for acute liver failure in the first months of age 
(OMIM #613070) [2]. Patients who survived this life-threatening period 
fully recovered and had a normal development without recurrence. To 
our knowledge, 26 patients with TRMU pathogenic variants have been 
published. Since the first description of reversible hepatic failure, only a 
few other phenotypes with extra-hepatic manifestations have been re-
ported. Leigh syndrome (LS), featured by hyperlactacidemia and sym-
metrical lesions in brainstem, basal ganglia and other brain structures, is 
the most common pediatric presentation of mitochondrial disease [3]. 
We present two recently diagnosed patients with acute liver failure 
caused by TRMU pathogenic variants associated to LS, a phenotypic 
combination not previously reported. 
2. Case reports 
We extensively searched the literature for patients with TRMU 
molecularly confirmed disease and clinical description. Supplementary 
Table 1 summarizes clinical, laboratory, radiological and genetic data 
described in TRMU patients in previously published patients (n = 26) 
and we added our two patients (Patient 1 is P27, Patient 2 is P28). 
Patient 1, a girl, was the second child of non-consanguineous par-
ents. She was born at term after an uneventful pregnancy. Her psycho-
motor development and growth parameters (weight, length and head 
circumference at +0.2 SD) were normal until the age of 3 months, when 
she presented a rapid deterioration and failure to thrive. She suffered 
progressive generalized hypotonia, fluctuating level of consciousness, 
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decreased intake, weight-loss (− 2 SD) and progressive hepatomegaly. 
Laboratory findings showed acute liver failure, metabolic acidosis and 
persistent high lactate in blood, urine and CSF. Brain MRI showed acute 
and symmetrical lesions of pontinus tracts, upper cerebellar peduncles, 
basal nuclei and white matter, with restriction on DWI and a lactate peak 
on MRS (See Fig. 1A-D). Abdominal ultrasound showed an increased size 
and echogenicity of the liver, without any other pathological findings. 
Echocardiography, EEG and ophthalmologic examinations were normal. 
The respiratory chain complex activities in muscle biopsy were 
decreased except for normal CII, and increased citrate synthase activity. 
Muscle biopsy findings suggested mitochondrial myopathy (see suppl 
table). Lactic acidosis correction and supplementation with carnitine, 
biotine and thiamine was initiated with transient clinical and 
biochemical improvement. After two months the patient was readmitted 
to PICU with severe hepatic failure, coagulopathy, tubulopathy and 
lactic acidosis, refractory to all treatments and she died at the age of 6 
months. 
Mitochondrial DNA sequencing was normal. Clinical whole exome 
sequencing (TruSight One®, Illumina, San Diego) demonstrated two 
mutations in trans in TRMU gene: c.160_161delTG:p.Cys54* (non-pre-
viously reported, but likely pathogenic according to ACMG criteria since 
it creates an stop codon) and c.680G > C:p.Arg227Thr (previously 
described in [4]). Parents were carriers of these variants. 
Patient 2, a boy, was the first child of non-consanguineous parents. 
After a non-complicated pregnancy, he was born at term with low birth- 
weight (− 2.7 SD). During the first 12 h of life he presented generalized 
hypotonia with severe lactic acidosis, progressive elevation of 
transaminases and coagulopathy. Brain MRI showed T2 hyperintense 
supra and infratentorial lesions affecting bilateral thalami, subthalamic 
nuclei and brainstem and a lactate peak on MRS (See Fig. 1E-O). Further 
metabolic investigations showed high lactate/pyruvate ratio, important 
elevation of intermediate metabolites of Krebs cycle in urine, and 
hyperalaninemia. Under the suspicion of a mitochondrial disorder, 
treatment with coenzyme Q, riboflavin, thiamine and biotin were 
initiated with no clinical improvement. He showed a refractory hyper-
lactacidaemia (15–20 mmol/L) and died at the age of 25 days from a 
multiple organ failure. The respiratory chain complexes activities were 
measured in muscle and, except for CII, all of them and also citrate 
synthase activity were decreased. When analyzing their ratio, most of 
them became normalized, so no significant alterations were detected. 
The low activity of all complexes and also of citrate synthase, could 
indicate a low number of mitochondria in the muscle. Mitochondrial 
DNA sequencing was normal. Exome Sequencing showed two patho-
genic variants in TRMU: c.2 T > A: p.Met1? (reported in [2]) and 
c.491delT: p.Leu164ProfsTer22 (non-previously reported, but also 
pathogenic according to ACMG rules due to frameshift change gener-
ating premature stop codon). Most relevant findings in patient’s nec-
ropsy were: massive hepatic steatosis, increase in heart thickness at the 
expense of groups of vacuolated and granular cytoplasm myocytes, 
among which conserved myocytes were identified, and severe spongi-
otic vacuolization in thalamus, midbrain, trunk and focal cerebellum. 
In summary, both patients presented an early onset Leigh syndrome 
and an acute liver failure with progression to multiorganic failure and 
fatal outcome due to TRMU variants, and can not be explained by other 
Fig. 1. MRI of patient 1 (P27 in the supplementary table) showed symmetrical lesions of pontinus tracts, upper cerebellar peduncles, basal nuclei and white matter 
with restriction in DWI (A-D). MRI of patient 2 (P28 in the suppl table) showed an increased lactate peak in the MRS (E), supra and infratentorial lesions affecting 
bilateral thalami, subthalamic nuclei and brainstem in DWI (F-J) and T2 (K-O). 
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genetic findings in the whole exome-sequencing. 
3. Discussion 
We report two recently diagnosed unrelated patients with TRMU 
pathogenic variants, associating LS and acute liver failure, a combina-
tion not previously reported. 
Classical presentation of TRMU pathogenic variants has been 
described to date in 26 patients with acute liver failure as the main 
phenotype, some of which share other clinical findings (Supplementary 
table) [2,5–12]. Almost all (24/26) reported patients suffered from he-
patic failure. One (P18) had a myopathic phenotype (ptosis, fatigability, 
bulbar involvement with feeding and respiratory difficulties at onset 
with complete recovery) and another (P20) a fatal heart failure in his 
first month of life. Other extrahepatic manifestations include a variable 
range of symptoms: reversible dilated cardiomyopathy and neph-
romegaly (P4), bulbar involvement with feeding difficulties (P18,P19), 
some degree of hypotonia (P15, P17, P18), hypothyroidism, macrocytic 
anemia and microcephaly (P21, P22), ichthyosis (P24), etc. Long-term 
outcome varies from complete recovery (19/26) to death due to liver, 
heart or multiorganic failure (7/26). When surviving the acute phase, 
most patients have a normal development and complete recovery. 
However, long term follow-up data are not available for all of these 
patients. Regarding biochemical findings, all patients showed increased 
serum lactate level (3.2–40.0 mmol/L), with variable range of lactate in 
CSF (from normal, to 3.9 mmol/L). Abnormal liver function was present 
in all patients (available data from 24/26) with variable degrees of 
transaminase elevation, coagulopathy, cholestasis or elevated alfa- 
fetoprotein. Liver biopsies (9/23) showed signs of mild to severe he-
patic involvement in biopsies taken several months after onset: onco-
cytic changes in the hepatocytes, focal steatosis and focal ballooning of 
cytoplasm, micronodular cirrhosis, canalicular cholestasis to patent 
signs of fibrosis, irregular cirrhosis with nodulation and macrovesicular 
steatosis. No normal hepatic biopsies were reported. Analysis of respi-
ratory chain enzyme activities demonstrated a combined respiratory 
chain complex deficiency in most of the cases with available data (11/ 
26). Brain MRI was performed in 17/26 patients. All except three were 
normal. P16 had a lactate peak in MRI with no lesions, P15 had myeli-
nation delay with normal MRS and P19 had a reversible T2 high signal in 
right thalamus with lactate peak in MRS. 
Our patients are similar to the ones reported in literature in terms of 
liver failure and abnormal laboratory findings. In contrast, our patients 
presented a neurological clinical onset consisted of an acute encepha-
lopathy and developmental regression (P1) and severe hypotonia from 
birth (P2). All two displayed symmetrical and bilateral lesions in MRI 
affecting different brain structures consistent with LS, with a lactate 
peak on MRS. Postmortem study in P2 demonstrated massive hepatic 
steatosis, also seen in liver biopsies of previous patients and spongiotic 
vacuolization in thalamus, midbrain, trunk and focal cerebellum as seen 
in LS [3]. Interestingly, this necropsy showed cardiac affection, despite 
the patient not having presented evident cardiological symptoms. Only 
two previous patients (P4, P20) were mentioned to have cardiological 
involvement. 
Clinical presentation of Leigh syndrome varies depending on the age 
of onset [13]. In typical infantile onset, initial nonspecific manifesta-
tions can be seen: vomiting, hypotonia, failure to thrive or develop-
mental delay, often with acute worsening of previous clinical state after 
a clinical event such as infection. On the other hand, liver involvement it 
is a very unusual clinical manifestation. Bilateral symmetrical lesions 
within the brainstem, basal ganglia and less frequent white matter, T2- 
W in MRI characterize the disease with elevated lactate in MRS [14]. 
Both clinical and neuroimaging features occurred in our two patients. 
Pathogenic variants in over 75 genes (nuclear and mitochondrial DNA), 
have been associated to Leigh syndrome [14], despite what, half of the 
cases remain without a genetic diagnosis [13]. Defects of nuclear DNA 
genes are the main cause of Leigh syndrome, with only 25% of all cases 
caused by mtDNA pathogenic variants. Both isolated and multiple 
complex deficiencies can be found, being these last ones mainly caused 
by mutations in more than 150 proteins implicated in mitochondrial 
translation, including TRMU [15]. Axial and/or peripheral hypotonia 
was described in four patients (P15, P16, P18 and P19), P25 had seizure- 
like episodes and mild developmental delay has been reported in P24 
and P26. Although neurological involvement has been described in some 
patients, none of them had brain lesions compatible with Leigh 
syndrome. 
TRMU encodes a protein that participates in the modification of 
mitochondrial tRNAs. Specifically, it is responsible for the 2-thiolation 
of the nucleotide at the wobble position of the tRNA-Lys, tRNA-Glu, 
and t-RNA-Gln [2]. Many other genes related to mitochondrial trans-
lation are identified to cause Leigh syndrome [13,14]. Similar patho-
genic mechanisms could be shared between these genes to explain Leigh 
syndrome in our patients, but further investigations are needed to un-
derstand why only a few patients with TRMU pathogenic variants 
developed this phenotype. 
Although most of the reported patients (19/26) experienced a partial 
or total recovery after the acute phase, all of our patients died during the 
first months of life. They presented severe neurological involvement and 
finally died from multiorganic failure. 
A possible explanation to clarify a genotype-phenotype correlation 
has been proposed [2]: patients carrying two missense variants (except 
those occurring in first methionine) seem to have better prognosis than 
when, nonsense, frameshift or splicing variants are present. Both pa-
tients carried nonsense and frameshift variants respectively, in com-
pound heterozygosity with known missense pathogenic variants. On the 
other hand, first descriptions of TRMU defects suggested increasing 
cysteine availability in later infancy as a possible explanation for clinical 
recovery [2]. Patient 2 had an abnormal birth weight, which may induce 
thinking that cysteine deficiency in maternal and neonatal nutrition 
could also be a potential contributor to a severe phenotype. However, 
patient 1 had normal weight before clinical deterioration at 3 months 
old. Therefore, we conclude that neither molecular findings nor 
maternal/neonatal nutrition seem reason enough to explain the clinical 
heterogeneity of the disorder. 
To conclude, TRMU gene sequencing should be considered in pa-
tients with Leigh syndrome, especially when liver involvement is pre-
sent, and also in patients with other mitochondrial phenotypes as 
progressive failure to thrive, mild-moderate psychomotor delay, mild 
liver involvement and metabolic acidosis with hyperlactacidemia. 
Further patient reports and more investigations are needed to explain 
this phenotypical variability even though carrying same pathogenic 
variants. Our report enlarges the phenotypical spectrum of TRMU 
disease. 
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